We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.
We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation.
By leveraging these assets and expertise, we are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.
Q3 2021 financial information – Revenues and cash
2021 annual revenues and cash situation 12/31/2021
Euronext Share Information€11.96 -2.92%
Last update: Oct 20, 2021 at 10:00 CET
Previous close: €12.32
Day High: €12.32
Day Low: €11.86
Inventiva was co-founded by Frédéric Cren, Chairman, CEO and Co-Founder and Pierre Broqua, Chief Scientific Officer in Dijon in 2012.
Both have strong expertise within the areas of research, development and strategy and held senior research and executive positions at both Fournier and Solvay prior to founding Inventiva.